SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-284535
Filing Date
2022-11-14
Accepted
2022-11-14 16:05:04
Documents
15
Period of Report
2022-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d419341d8k.htm   iXBRL 8-K 35001
2 EX-99.1 d419341dex991.htm EX-99.1 47654
3 EX-99.2 d419341dex992.htm EX-99.2 7816
7 GRAPHIC g419341g1112075309980.jpg GRAPHIC 5399
  Complete submission text file 0001193125-22-284535.txt   238206

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20221110.xsd EX-101.SCH 2885
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20221110_lab.xml EX-101.LAB 18739
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20221110_pre.xml EX-101.PRE 11727
9 EXTRACTED XBRL INSTANCE DOCUMENT d419341d8k_htm.xml XML 3459
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 221385050
SIC: 2834 Pharmaceutical Preparations